Rani Therapeutics Holdings, Inc. (RANI)

7.15 -0.31 (-4.16%) At close: 04:00PM EDT

Rani Therapeutics Holdings, Inc.

2051 Ringwood Avenue
San Jose, CA 95131
United States
408 457 3700
https://www.ranitherapeutics.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 140

Key executives

Name	Title	Pay	Exercised	Year born
Mr. Mir A. Imran	Executive Chairman	80k	N/A	1957
Mr. Talat Imran	CEO & Director	450k	N/A	1982
Mr. Svai S. Sanford	Chief Financial Officer	416k	N/A	1970
Dr. Mir Hashim	Chief Scientific Officer	416k	N/A	1960
Mr. Eric Groen	General Counsel	N/A	N/A	1971
Ms. Bella Vazquez	Vice President of Human Resources	N/A	N/A	N/A
Ms. Kate McKinley M.B.A.	Chief Business Officer	N/A	N/A	1977
Ms. Arvinder Dhalla	Vice President of Clinical Development	N/A	N/A	N/A

Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company that develops orally administered biologics for patients, physicians, and healthcare systems in the United States. The company develops the RaniPill capsule, a drug-agnostic oral delivery platform to deliver a variety of drug substances, including oligonucleotides, peptides, proteins, and antibodies. Its product pipeline includes RT-102, a parathyroid hormone that is in Phase I clinical trial for the treatment of osteoporosis; RT-105, an anti-TNF-alpha antibody that is in preclinical studies to treat psoriatic arthritis; RT-110, a parathyroid hormone for the treatment of hypoparathyroidism; and RT-111, an ustekinumab biosimilar for the treatment of various inflammatory conditions. Rani Therapeutics Holdings, Inc. was founded in 2012 and is headquartered in San Jose, California.

Corporate governance

Rani Therapeutics Holdings, Inc.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.